2009
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas
Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, PapillaryCell Line, TumorCell SeparationClaudin-3Enzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene LibraryHumansImmunoglobulin FragmentsMembrane ProteinsMicroscopy, ConfocalOvarian NeoplasmsSelf-Sustained Sequence ReplicationSensitivity and SpecificitySurface Plasmon ResonanceUterine Cervical NeoplasmsConceptsClaudin-3Uterine serous carcinoma cell linesSerous papillary carcinomaHuman antibody phage display libraryNovel therapeutic targetEnzyme-linked immunosorbent assayEnzyme-linked immunosorbentHuman single-chain antibody fragmentAntibody phage display libraryCarcinoma cell linesUterine carcinomaNovel antitumor agentsPapillary carcinomaTherapeutic targetSingle-chain antibody fragmentHuman antibodiesHuman malignanciesImmunosorbent assayConformational epitopesPhage display libraryCarcinomaCell linesSurface immunofluorescenceCell surface immunofluorescenceAntitumor agents
2005
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98: 92-98. PMID: 15904949, DOI: 10.1016/j.ygyno.2005.03.016.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaIL-6 gene expression levelsEndometrioid carcinomaInterleukin-6Primary endometrioid carcinomaEnzyme-linked immunosorbent assayEndometrial carcinomaHealthy femalesUSPC patientsMean serum IL-6 levelPrimary USPC cell linesIL-6 serum concentrationsSerum IL-6 levelsAnti-tumor immune functionBenign abdominal diseasesChemotherapy-resistant variantsControl endometrial cellsNormal healthy femalesSerous papillary histologyUSPC cell linesIL-6 concentrationsIL-6 levelsBenign disease patientsHigher serum levelsSerous papillary carcinoma
1999
Secretion of vascular endothelial growth factor in ovarian cancer.
Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. European Journal Of Gynaecological Oncology 1999, 20: 177-81. PMID: 10410879.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorOvarian cancer patientsCancer patientsOvarian carcinoma cell linesEnzyme-linked immunosorbent assayEndothelial growth factorOvarian cancerCarcinoma cell linesAscitic fluidFluid accumulationLow vascular endothelial growth factorVEGF secretionGrowth factorTumor-Induced ImmunosuppressionVascular endothelial cell functionDefective immune functionHigh-grade malignancyLow-grade tumorsHuman ovarian carcinoma cell linesAnti-angiogenic treatmentNovel therapeutic approachesPeritoneal fluid accumulationAction of VEGFCell linesAscitic fluid accumulation